Clinical development of recombinant human interleukin-11 to treat chemotherapy-induced thrombocytopenia.
Recombinant human interleukin-11 stimulates megakaryocytopoiesis in vitro and platelet production in vivo. A clinical program to investigate the use of recombinant human interleukin-11 in patients with chemotherapy-induced thrombocytopenia began in 1992. These studies show the potential of recombinant human interleukin-11 as a treatment for chemotherapy-induced thrombocytopenia. The other activities of recombinant human interleukin-11, such as its ability to ameliorate mucositis in myelosuppressed animal models, may contribute to its clinical benefits in patients receiving chemotherapy.
Kaye
J A
JA
Genetics Institute, Cambridge, MA 02140, USA.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D006801:Humans; D017370:Interleukin-11 / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000188:drug therapy* / Q000209:etiology
D017370:Interleukin-11; D011994:Recombinant Proteins